Risk/Benefit profile of arsenic trioxide

Oncologist

Volumn 6, Issue SUPPL. 2, 2001, Pages 29-32

  Rust, D M ^a   Soignet, S L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; APL differentiation syndrome; Arsenic trioxide; Hyperleukocytosis; QT interval

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; CHINA; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; LEUKOCYTOSIS; LONG QT SYNDROME; PRIORITY JOURNAL; RASH; REMISSION; RISK BENEFIT ANALYSIS;

EID: 0035031113     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_2-29     Document Type: Conference Paper

References (23)

1. Delicious poison: Arsenic trioxide for the treatment of leukemia
2. Metal carcinogenesis: Mechanistic implications
3. Arsenic
4. Arsenic and arsenic compounds
5. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression
6. Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species
7. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
8. Arsenicals in hematologic cancers
9. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
10. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
11. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
12. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
13. 3) induce differentiation, but not apoptosis, of retinoic acid (RA)-resistant APL in vitro and in vivo by modulating JAK2 tyrosine kinase and bax
14. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
15. Involvement of the ceramide pathway in the cytotoxicity of arsenic trioxide and interferon alpha in HTLV-I transformed cells
16. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): The combined results and follow-up from the U.S. pilot and multicenter trials
17. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia
18. The "retinoic acid syndrome" in acute promyelocytic leukemia
19. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
20. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid
21. 3 safety in the treatment of pediatric patients with acute premyelocytic leukemia (APL)
22. Arsenic carcinogenesis in animals and in humans: Mechanistic, experimental, and epidemiological evidence